Literature DB >> 17220821

99mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy.

S Rottey1, D Loose, L Vakaet, C Lahorte, H Vermeersch, S Van Belle, C Van de Wiele.   

Abstract

AIM: The aim of this study was to report on the relationship between preradiotherapy and prechemotherapy 99mTc-HYNIC Annexin-V tumor uptake values, reflecting ongoing apoptosis, and outcome to radiotherapy and/or chemotherapy.
METHODS: Twenty-three cancer patients underwent staging examinations and a 99mTc-HYNIC Annexin-V scintigraphy and subsequent radiotherapy and/or chemotherapy. Tumor-to-background ratios derived from tomographic 99mTc-HYNIC Annexin-V images were related to treatment outcome as assessed by RECIST criteria.
RESULTS: Six patients underwent radiotherapy or radiochemotherapy: 4 exhibited response to treatment, 1 had stable, and 1 progressive disease. Corresponding tumor-to-background ratio's were respectively >or=2.3 (in responders), 1.2 in the patient presenting with stable disease and 1 in the patient presenting with progressive disease. Seventeen patients were treated by chemotherapy alone: 8 were progressive, 1 patient presented with stable disease and 8 responded to treatment. In 1/8 progressive patients a tumor-to-background ratio of 1.4 was found, the others showed no uptake. In the patient presenting with stable disease a ratio of 0.1 was found. In the 8 responders, 7 patients had a tumor-to-background ratio >or=1.3 whereas in 1 patient a ratio of 0.3 was found. Tumor-to-background ratios in responders (complete plus partial) (median 2.5, range: 0.3-4.2) were significantly higher when compared to those obtained in non-responders (stable plus progressive disease) (median 1, range: 0.1-1.4) (P<0.001).
CONCLUSION: The findings presented suggest that 99mTc-HYNIC Annexin-V pretreatment uptake may be useful to predict response to chemo- and radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17220821

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  14 in total

Review 1.  (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.

Authors:  Tarik Z Belhocine; Francis G Blankenberg; Marina S Kartachova; Larry W Stitt; Jean-Luc Vanderheyden; Frank J P Hoebers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-16       Impact factor: 9.236

Review 2.  Apoptosis and apoptotic body: disease message and therapeutic target potentials.

Authors:  Xuebo Xu; Yueyang Lai; Zi-Chun Hua
Journal:  Biosci Rep       Date:  2019-01-18       Impact factor: 3.840

3.  Preclinical imaging of therapy response using metabolic and apoptosis molecular imaging.

Authors:  Marijke De Saint-Hubert; Huijun Wang; Ellen Devos; Kathleen Vunckx; Lin Zhou; Chris Reutelingsperger; Alfons Verbruggen; Luc Mortelmans; Yicheng Ni; Felix M Mottaghy
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 4.  Phosphatidylserine targeting for diagnosis and treatment of human diseases.

Authors:  Kristof Schutters; Chris Reutelingsperger
Journal:  Apoptosis       Date:  2010-09       Impact factor: 4.677

Review 5.  Molecular imaging: 18F-FDG PET and a whole lot more.

Authors:  Todd E Peterson; H Charles Manning
Journal:  J Nucl Med Technol       Date:  2009-08-19

6.  Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.

Authors:  Jeffrey Wojton; Zhengtao Chu; Haritha Mathsyaraja; Walter H Meisen; Nicholas Denton; Chang-Hyuk Kwon; Lionel Ml Chow; Mary Palascak; Robert Franco; Tristan Bourdeau; Sherry Thornton; Michael C Ostrowski; Balveen Kaur; Xiaoyang Qi
Journal:  Mol Ther       Date:  2013-06-04       Impact factor: 11.454

Review 7.  Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.

Authors:  R Adam Smith; Saffet Guleryuz; H Charles Manning
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

8.  Radionuclide Imaging of Apoptosis in Malignancies: Promise and Pitfalls of Tc-Hynic-rh-Annexin V Imaging.

Authors:  M S Kartachova; M Verheij; B L van Eck; C A Hoefnagel; R A Valdes Olmos
Journal:  Clin Med Oncol       Date:  2008-03-25

9.  In vivo99mTc-HYNIC-annexin V imaging of early tumor apoptosis in mice after single dose irradiation.

Authors:  Ming-fang Guo; Yaqing Zhao; Rong Tian; Lin Li; Leiming Guo; Feng Xu; Yong-mei Liu; Yong-bo He; Sen Bai; Jin Wang
Journal:  J Exp Clin Cancer Res       Date:  2009-10-08

10.  99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.

Authors:  Frédéric L W V J Schaper; Chris P Reutelingsperger
Journal:  Cancers (Basel)       Date:  2013-05-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.